bloody nose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient received BNT162b2 (BNT162B2), on 04Jun2022 at 15:00 as dose 5 (booster), single (Lot number: FM7553), in arm for covid-19 immunisation. The patient's relevant medical history included: "Dental" (unspecified if ongoing), notes: Dental; "Scale" (unspecified if ongoing), notes: Scale; "Gout" (unspecified if ongoing); "Cholesterol" (unspecified if ongoing); "Hyperparathyroid" (unspecified if ongoing); "Rosacea" (unspecified if ongoing); "Edema" (unspecified if ongoing); "Osteoporosis" (unspecified if ongoing); "Thyroid Replacement" (unspecified if ongoing), notes: Thyroid Replacement; "Hypertension" (unspecified if ongoing); "Heart" (unspecified if ongoing), notes: Heart; "Antirejection" (unspecified if ongoing), notes: Antirejection; "Bovine valve 2011 need new one soon", start date: 2011 (unspecified if ongoing), notes: Bovine valve 2011 need new one soon. Concomitant medication(s) included: PREDNISONE taken for immunosuppression; MYCOPHENOLATE MOFETIL taken for immunosuppression; CYCLOSPORINE taken for immunosuppression; METOPROLOL SUCCINATE taken for cardiac disorder; LABETALOL HCL taken for cardiac disorder; ASPIRIN [ACETYLSALICYLIC ACID] taken for cardiac disorder; K-LOR taken for cardiac disorder; AMLODIPINE taken for hypertension; L-THYROXINE [LEVOTHYROXINE] taken for thyroid disorder; VIT D [VITAMIN D NOS] taken for osteoporosis; CALCIUM taken for osteoporosis; FUROSEMIDE taken for oedema; NORITATE topical taken for rosacea; TAZORAC topical taken for rosacea; SEVELAMER CARBONATE taken for hyperparathyroidism; PRAVASTATIN SODIUM taken for blood cholesterol; EZETIMIBE taken for blood cholesterol; ALLOPURINOL taken for gout; TRIAMCINOLONE ACETONIDE taken for skin exfoliation; AMOXICILLIN [AMOXICILLIN SODIUM] taken for tooth disorder. Vaccination history included: BNT162b2 (Dose: 1st, Time (24hrs): 11:15, Site and Route of injection:, Anatomical site of injection: Arm, Route of administration: Intramuscular, Batch/Lot number: EL9261), administration date: 29Jan2021, for COVID-19 Immunization, reaction(s): "After each vaccination I had a bloody nose"; BNT162b2 (Dose: 2nd , Time (24hrs): 17:30, Site and Route of injection:, Anatomical site of injection: Arm, Batch/Lot number: WT EM9809), administration date: 18Feb2021, for COVID-19 Immunization, reaction(s): "After each vaccination I had a bloody nose"; BNT162b2 (Dose: 3rd , Time (24hrs): 15:00, Site and Route of injection:, Anatomical site of injection: Arm, Batch/Lot number: FC3181), administration date: 16Aug2021, for COVID-19 Immunization, reaction(s): "After each vaccination I had a bloody nose"; BNT162b2 (Dose: 4th, Time (24hrs): 12:00, Site and Route of injection:, Anatomical site of injection: Arm, Batch/Lot number: FH8020), administration date: 22Jan2022, for COVID-19 Immunization, reaction(s): "After each vaccination I had a bloody nose". The following information was reported: EPISTAXIS (non-serious), outcome "recovered", described as "bloody nose".  Therapeutic measures were not taken as a result of epistaxis.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300057499 same reporter/patient/drug, different doses/AE;US-PFIZER INC-PV202200098796 same patient, same drug, different dose/events(5th dose);US-PFIZER INC-PV202200112909 same patient, same drug,event/ different dose;US-PFIZER INC-202201337655 same reporter/patient/event, different doses;US-PFIZER INC-202201337656 same reporter/patient/event, different doses;